Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Silodosin to Facilitate Passage of Urinary Stones

ClinicalTrials.gov ID: NCT01144949

Public ClinicalTrials.gov record NCT01144949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage

Study identification

NCT ID
NCT01144949
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Watson Pharmaceuticals
Industry
Enrollment
239 participants

Conditions and interventions

Interventions

  • silodosin Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Jun 30, 2012
Completion
Jun 30, 2012
Last update posted
Aug 10, 2014

2010 – 2012

United States locations

U.S. sites
27
U.S. states
13
U.S. cities
27
Facility City State ZIP Site status
Watson Investigational Site Birmingham Alabama
Watson Investigational Site Anchorage Alaska
Watson Investigative Site Mission Hills California
Watson Investigational Site Murrieta California
Watson Investigational Site San Diego California
Watson Investigational Site Daytona Beach Florida
Watson Investigational Site Gainesville Florida
Watson Investigational Site Orange City Florida
Watson Investigative Site Overland Park Kansas
Watson Investigative Site North Kansas City Missouri
Watson Investigational Site Hackensack New Jersey
Watson Investigational Site Mount Laurel New Jersey
Watson Investigational Site Sewell New Jersey
Watson Investigational Site Voorhees Township New Jersey
Watson Investigational Site Albany New York
Watson Investigational Site Garden City New York
Watson Investigational Site New York New York
Watson Investigational Site Plainview New York
Watson Investigational Site Syracuse New York
Watson Investigational Site Cincinnati Ohio
Watson Investigational Site Columbus Ohio
Watson Investigational Site Bala-Cynwyd Pennsylvania
Watson Investigational Site Lancaster Pennsylvania
Watson Investigational Site Myrtle Beach South Carolina
Watson Investigational Site Dallas Texas
Watson Investigational Site San Antonio Texas
Watson Investigational Site Virginia Beach Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01144949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2014 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01144949 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →